UNS pipeline is led by UB-311, an immunotherapeutic vaccine for Alzheimer’s Disease currently in Phase II trials. UNS has developed a pipeline of additional vaccines leveraging the proprietary UBITh vaccine platform for other neurodegenerative disease targets including tau and alpha-synuclein. These programs are currently in pre-clinical stage.

In addition, UNS is actively looking to in-license additional programs in pre-clinical or Phase I.